SS-31 (Elamipretide)
SS-31 (Elamipretide) is a mitochondrial function peptide used in evidence-based, physician-supervised protocols. Use for mitochondrial dysfunction, heart failure, age-related energy decline, ischemia-reperfusion injury, and neuroprotection.
What is SS-31 (Elamipretide)?
Cardiolipin-targeting tetrapeptide. Selectively concentrates on inner mitochondrial membrane, stabilizes cardiolipin structure, preserves electron transport chain efficiency, reduces mitochondrial ROS, and prevents apoptosis from mPTP opening. 3x/year, 22-day cycles. Best used BEFORE MOTS-c cycle (primes mitochondria for gene expression).
Uses & clinical decision logic
Use for mitochondrial dysfunction, heart failure, age-related energy decline, ischemia-reperfusion injury, and neuroprotection.
SS-31 (Elamipretide) dosage & administration
| Vial size | BAC water | Dosing range | Units / dose | Frequency | Route |
|---|---|---|---|---|---|
| 10mg | 1mL | 5mg | 50 units | Daily x 22 days (11 bottle cycle) | SubQ |
Safety & contraindications
Minimal — well-tolerated in clinical trials.
Stacking & combinations
Sequence: SS-31 → then MOTS-c cycle. Compatible with NAD+, Humanin, and AICAR.
Related peptides
Frequently asked questions
What is SS-31 (Elamipretide) used for?
Use for mitochondrial dysfunction, heart failure, age-related energy decline, ischemia-reperfusion injury, and neuroprotection.
What is the typical SS-31 (Elamipretide) dosage?
Common dosing ranges from 5mg (Daily x 22 days (11 bottle cycle), SubQ). Exact dosing is individualized and set by a licensed physician.
How is SS-31 (Elamipretide) administered?
SS-31 (Elamipretide) is typically administered via SubQ.
What are the contraindications for SS-31 (Elamipretide)?
Minimal — well-tolerated in clinical trials.
Build a physician-supervised protocol around your goal — no gatekeeping, real doctors, 503A compounding pharmacies.
Build your protocol →This page is for educational purposes only and is not medical advice. Peptide therapies described here are provided under physician supervision through 503A compounding pharmacies. Many peptides are not FDA-approved for the uses described. Do not start, stop, or change any protocol without consulting a licensed physician.